Please login to the form below

Not currently logged in
Email:
Password:

Edward Hodgkin elected chair of UK biotech association

He will take up his new role at the BIA in October

BIA Ed HodgkinThe UK's BioIndustry Association (BIA) has elected Edward Hodgkin to be its new chair, succeeding Tim Edwards.

Hodgkin has been a non-executive director of the BIA since 2010 and currently serves on the Association's executive committee.

His career in pharma and biotech has so far spanned more than 20 years, during which time he has held a variety of scientific, business and management roles in the US and UK.

Hodgkin is currently a partner at the Wellcome Trust's independent subsidiary Syncona Partners, where his role is to create and lead new life science ventures. Prior to that he spent five years at Cambridge therapeutics company Biotica Technology as its CEO. 

He said:
"While our members face many challenges, not least being access to capital, there is a fantastic opportunity to put life sciences at the forefront of the nation's recovering economy. Government, private enterprise and the public sector are aligned in this ambition, and the BIA is playing a central role in facilitating that."

His predecessor, Tim Edwards, served as BIA chair for three years and will remain a member of the Association's board.

Edwards said:
"I am delighted that Ed has been elected as the new chairman of the BIA. His experience in the UK life sciences sector will be of great benefit to the organisation and its members. 

 “The BIA continues to be the leading advocacy group for the UK's innovative bioscience companies of all sizes, and I thank Steve and his team for all their work on behalf of our members."

1st July 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics